Kinnate Biopharma (DB:6KB) - Stock Price, News & Analysis

6KB Stock Overview

6KB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Kinnate Biopharma Inc. Competitors

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

4SC

DB:VSC

€50.2m

Medigene

XTRA:MDG1

€17.4m

Price History & Performance

Summary of all time highs, changes and price drops for Kinnate Biopharma
Historical stock prices
Current Share Price	US$2.42
52 Week High	US$2.44
52 Week Low	US$2.22
Beta	1.34
11 Month Change	2.54%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	3.42%

Recent updates

Shareholder Returns

	6KB	DE Biotechs	DE Market
7D	0%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Return vs Industry: Insufficient data to determine how 6KB performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 6KB performed against the German Market.

Price Volatility

Is 6KB's price volatile compared to industry and market?
6KB volatility
6KB Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6KB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6KB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	94	Nima Farzan	www.kinnate.com

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Kinnate Biopharma Inc. Fundamentals Summary

How do Kinnate Biopharma's earnings and revenue compare to its market cap?
6KB fundamental statistics
Market cap	€115.51m
Earnings (TTM)	-€103.98m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.1x

P/E Ratio

Is 6KB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6KB income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$112.65m
Earnings	-US$112.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.39
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 6KB perform over the long term?

See historical performance and comparison

Kinnate Biopharma DB:6KB Stock Report